Fig. 1

The inhibition of the mevalonate pathway suppresses cell vitality in human IGROV-1 and A2780 ovarian cancer cells. a IGROV-1 and A2780 cells were treated for 48 h and 24 h, respectively, with increasing concentrations of atorvastatin (ATO), simvastatin (SIM), rosuvastatin (ROSU) or zoledronic acid (ZOL). The inhibition of the mevalonate pathway was assessed by detection of Ras-related protein 1 (Rap1a, ungeranylated form is detected) and unfarnesylated Rat sarcoma (Ras; upper band) using Western blot. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control. The figures show representative blots which were cropped from original images. Full-length blots are presented in Suppl. Fig. 5. Images were detected using GelCapture 7.0.18 software. b IGROV-1 and A2780 cells were treated with increasing concentrations of ATO, SIM, ROSU, or ZOL for 48 h. Cell vitality was assessed by CellTiterBlue® assay. Data are shown as mean ± SEM of at least three individual experiments. (*p < 0.05; **p < 0.01; ***p < 0.001)